Flagging investor confidence in the traditional pharmaceutical model in the years following its mega-merger convinced GlaxoSmithKline that it needed to execute drastic change. Brought into the corporate team to help make it happen, chief strategy officer David Redfern tells Elizabeth Sukkar how a more aggressive approach has refocused GSK on R&D metrics that deliver true value.
In the past 10 years GlaxoSmithKline has seen its share price as high as £19.25 in December 2000, immediately after its mega-merger, falling to £11.04 in May 2008, the month...